



BEST AVAILABLE COPY

Docket No.: 48551(1758)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Jin-an JIAO et al.

Examiner: Dr. J. Vollano

Serial No.: 09/406,269

Group: 1614

Filed: September 24, 1999

For: PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
THEREOF

Honorable Commissioner of Patents
and Trademarks
Washington, DC 20231

CERTIFICATE OF MAILING

I, Patricia A. Barnes, hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office, as First Class Mail, postage prepaid, on **June 26, 2000**, in an envelope addressed to the: Assistant Commissioner for Patents, Washington, DC 20231.


Patricia A. Barnes

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

Applicants respond as follows to the Restriction Requirement as set forth in the Office Action dated May 25, 2000.

Applicants respectfully request reconsideration of the Restriction Requirement. In particular, it is believed the following three Groups could be examined together with undue burden: Group I ("A method for treating a mammal with an effective amount of at least one TF blocking compound to treat any disease that is not found in claim 2"), Group II ("A method for treating a mammal with an effective amount of at least one TF blocking compound to treat) and Group II, second occurrence ("A method for

BEST AVAILABLE COPY


blocking or inhibiting tissue factor-dependent activation of factor X and or factor IX). As noted in the Restriction, those Groups have overlapping classification; hence, the search and examination of those Groups together should not impose an undue burden.

Moreover, the Restriction includes thirteen different Groups. Clearly, substantial expense and time would be required by both Applicants and the PTO if separate divisional applications are required to be filed to pursue the subject matters of those thirteen Groups.

To provide a complete response, Applicants hereby elect with traverse Group II as set forth in the Restriction, which presently includes claims 1 (in part), claim 2, claim 3-4, and claims 5-12 (in part), and described in the Restriction as "A method for treating a mammal with an effective amount of at least one TF blocking compound to treat a cardiovascular disease, a blood coagulation disorder, a cell proliferation disorder, post-operative complication, an immune disorder, atherosclerosis, inflammation or cancer. The present election is made solely to comply with the Office Action and should not be construed as a surrender of any subject matter in the application. The right to file divisional applications on the non-elected claims is reserved.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,




Peter F. Corless (Reg. No. 33,860)
Kerri P. Schray (Reg. No. P-47,066)
Dike, Bronstein, Roberts & Cushman LLP
130 Water Street
Boston, MA 02109
Ph: (617) 523-3400
Fax: (617) 523-6440

BEST AVAILABLE COPY

JUN 30 2000

1614



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
48551 (1758)

In Re Application Of: Jin-an JIAO, et al..

Serial No.
09/406,269

Filing Date
September 24, 1999

Examiner
Dr. J. Vollano

Group Art Unit
1614

Title: PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE THEREOF

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Response To Restriction Requirement;
Return postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Signature

Dated: June 26, 2000

Peter F. Corless (Reg. No. 33,860)
Kerri P. Schray (Reg. No. P-47,066)
Dike, Bronstein, Roberts & Cushman, LLP
130 Water Street
Boston, MA 02109
Tel. (617) 523-3400

I certify that this document and fee is being deposited
on **06/26/00** with the U.S. Postal Service as
first class mail under 37 C.F.R. 1.8 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C.
20231.

Signature of Person Mailing Correspondence

Patricia A. Barnes

Typed or Printed Name of Person Mailing Correspondence

CC: